XLXiaowei Li

Xiaowei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaowei Li has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Jianzeng Dong

    Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

    8 shared publications
  • Jianchao Zhang

    6 shared publications
  • Mengduan Liu

    Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Henan Key Laboratory of Hereditary Cardiovascular Diseases, Zhengzhou 450052, China

    6 shared publications
  • Wanrong Fu

    Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China

    5 shared publications
  • Yangyang Liu

    Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Henan Key Laboratory of Hereditary Cardiovascular Diseases, Zhengzhou 450052, China

    5 shared publications
  • Xiaoxu Tian

    Department of Cardiology (G.-J.Z., H.-T.S., X.T., L.K., H.L., G.L., H.T., Y.Z.), The First Affiliated Hospital of Zhengzhou University, China

    4 shared publications

Latest Publications

  • USP10 Deubiquitinates MTX2 to Suppress cGAS-STING Signaling in MI

    by Guo-Jun Zhao, Hui-Ting Shi, Xiaoxu Tian, Xun-Xun Chen, Lingyao Kong, Huan Li, Jia Wang, Yangyang Liu, Mengduan Liu, Xiaowei Li, et al.

    BACKGROUND: Myocardial infarction (MI) results in 3 distinct regions within the left ventricle: the infarct zone, the border zone (BZ), and the remote zone. A major focus of MI research is investigating the intrinsic mechanisms in the BZ to alleviate myocardial injury. USP10 (ubiquitin-specific peptidase 10) expression is reduced in BZ cardiomyocytes, indicating potential for targeted therapeutic intervention. METHODS: Isolated BZ cardiomyocytes and hypoxia-treated neonatal rat cardiomyocytes were used to investigate the expression of USP10 in MI. Cultured neonatal rat cardiomyocytes and genetically engineered mice were used to assess the importance of USP10 in the context of MI. Immunoprecipitation mass spectrometry and ubiquitination assays were used to explore the mechanisms by which USP10 suppresses the cGAS (cyclic GMP-AMP synthase) stimulator of interferon genes (STING) pathway. RESULTS: Our study reveals that USP10 is critical in protecting against cardiac injury following MI. Specifically, USP10 mitigates MI-induced mitochondrial dysfunction and prevents the release of mitochondrial DNA into the cytosol, thereby inhibiting the activation of the cGAS-STING signaling pathway. Additionally, USP10 deubiquitinates the K48-linked ubiquitination of MTX2 (metaxin 2), thus enhancing MTX2 protein stability. We identified K93 as a critical ubiquitination site on MTX2 through mutagenesis analysis. Importantly, our findings demonstrate that the MTX2-K93R mutation rectifies USP10 loss-induced exacerbation of MI. CONCLUSIONS: This study identifies USP10 as a novel regulator of the cGAS-STING signaling pathway in MI. Moreover, our findings demonstrate that a decrease in USP10 in the BZ cardiomyocytes can be therapeutically targeted to mitigate cardiac injury in MI.


  • Open Access

    Programmed ribosomal frameshifting during PLEKHM2 mRNA decoding generates a constitutively active proteoform that supports myocardial function

    by Gary Loughran, Raffaella De Pace, Ningyu Ding, Jianchao Zhang, Irwin Jungreis, Gionmattia Carancini, Jonathan M. Mudge, Ji Wang, Manolis Kellis, John F. Atkins, et al.

    Programmed ribosomal frameshifting is a process where a proportion of ribosomes change their reading frame on an mRNA. While frameshifting is commonly used by viruses, very few phylogenetically conserved examples are known in nuclear encoded genes. Here, we report a +1 frameshifting event during decoding of the human gene PLEKHM2 that provides access to a second internally overlapping ORF. The new carboxyl-terminal domain of this frameshift protein forms an α helix, which relieves PLEKHM2 from autoinhibition and allows it to move to the tips of cells without activation by ARL8. Reintroducing both the canonically translated and frameshifted protein are necessary to restore normal contractile function of PLEKHM2 knockout cardiomyocytes, demonstrating the necessity of frameshifting for normal cardiac activity.


  • Open Access

    Decreased energy production and Ca2+ homeostasis imbalance induce myocardial hypertrophy in PDHA1-deficient human pluripotent stem cell derived cardiomyocytes

    by Jihong Sun, Chongpei Hua, Jianchao Zhang, Ningyu Ding, Yangyang Liu, Mengduan Liu, Hailong Tao, Jianzeng Dong, Xiaoyan Zhao, Xiaowei Li


  • Open Access

    TAB2 deficiency induces dilated cardiomyopathy by promoting mitochondrial calcium overload in human iPSC-derived cardiomyocytes

    by Wenrui Sun, Jianchao Zhang, Shuang Li, Wanrong Fu, Yangyang Liu, Mengduan Liu, Jianzeng Dong, Xiaoyan Zhao, Xiaowei Li

    Background: TGF-β-activated kinase 1 binding protein 2 (TAB2) is an intermediary protein that links Tumor necrosis factor receptor 1 (TNFR1) and other receptor signals to the TGF-β-activated kinase 1 (TAK1) signaling complex. TAB2 frameshift mutations have been linked to dilated cardiomyopathy (DCM), while the exact mechanism needs further investigation. Methods: In this study, we generated a TAB2 compound heterozygous knockout cell line in induced pluripotent stem cells (iPSCs) derived from a healthy individual using CRISPR/Cas9 technology. IPSCs are not species-dependent, are readily accessible, and raise fewer ethical concerns. Results: TAB2 disruption had no impact on the cardiac differentiation of iPSCs and led to confirmed TAB2 deficiency in human iPSC-derived cardiomyocytes (hiPSC-CMs). TAB2-deficient hiPSC-CMs were found to develop phenotypic features of DCM, such as distorted sarcomeric ultrastructure, decreased contractility and energy production, and mitochondrial damage at day 30 post differentiation. Paradoxically, TAB2 knockout cell lines showed abnormal calcium handling after 40 days, later than reduced contractility, suggesting that the main cause of impaired contractility was abnormal energy production due to mitochondrial damage. As early as day 25, TAB2 knockout cardiomyocytes showed significant mitochondrial calcium overload, which can lead to mitochondrial damage. Furthermore, TAB2 knockout activated receptor-interacting protein kinase 1 (RIPK1), leading to an increase in mitochondrial calcium uniporter (MCU) expression, thereby augmenting the uptake of mitochondrial calcium ions. Finally, the application of the RIPK1 inhibitor Nec-1s prevents the progression of these phenotypes. Conclusions: In summary, TAB2 abatement cardiomyocytes mimic dilated cardiomyopathy in vitro. This finding emphasizes the importance of using a human model to study the underlying mechanisms of this specific disease. More importantly, the discovery of a unique pathogenic pathway introduces a new notion for the future management of dilated cardiomyopathy.


  • Open Access

    Mitochondrial transplantation rescues Ca2+ homeostasis imbalance and myocardial hypertrophy in SLC25A3-related hypertrophic cardiomyopathy

    by Shuang Li, Jianchao Zhang, Wanrong Fu, Jinhua Cao, Zhonggen Li, Xiaoxu Tian, Meng Yang, Jing Zhao, Chuchu Wang, Yangyang Liu, et al.


  • Open Access

    Establishment of heterozygous LMOD2 knockout human embryonic stem cell line (ZZUNEUi022-A-1) using CRISPR/Cas9 system

    by Chunjin Zhang, Jing Li, Yipu Sai, Haitao Su, Youxu Jiang, Lihua Zhang, Liguo Jian, Hui Zhang, Guangli Guo, En Li, et al.

  • Open Access

    Generation of a human induced pluripotent stem cell line ZZUNEUi030-A from a female patient carrying a heterozygous CALM2 (c.395 A > T) mutation

    by Chongpei Hua, Wenrui Sun, Chunjin Zhang, Xiaoxu Tian, Xintong Qin, Jianzeng Dong, Xiaowei Li

  • Open Access

    Frameshift variants in C10orf71 cause dilated cardiomyopathy in human, mouse, and organoid models

    by Yang Li, Ke Ma, Zhujun Dong, Shijuan Gao, Jing Zhang, Shan Huang, Jie Yang, Guangming Fang, Yujie Li, Xiaowei Li, et al.

    Research advances over the past 30 years have confirmed a critical role for genetics in the etiology of dilated cardiomyopathies (DCMs). However, full knowledge of the genetic architecture of DCM remains incomplete. We identified candidate DCM causal gene, C10orf71, in a large family with 8 patients with DCM by whole-exome sequencing. Four loss-of-function variants of C10orf71 were subsequently identified in an additional group of492 patients with sporadic DCM from 2 independent cohorts. C10orf71 was found to be an intrinsically disordered protein specifically expressed in cardiomyocytes. C10orf71 -KO mice had abnormal heart morphogenesis during embryonic development and cardiac dysfunction as adults with altered expression and splicing of contractile cardiac genes. C10orf71 -null cardiomyocytes exhibited impaired contractile function with unaffected sarcomere structure. Cardiomyocytes and heart organoids derived from human induced pluripotent stem cells with C10orf71 frameshift variants also had contractile defects with normal electrophysiological activity. A rescue study using a cardiac myosin activator, omecamtiv mecarbil, restored contractile function in C10orf71 -KO mice. These data support C10orf71 as a causal gene for DCM by contributing to the contractile function of cardiomyocytes. Mutation-specific pathophysiology may suggest therapeutic targets and more individualized therapy.


  • Open Access

    PLEKHM2 deficiency induces impaired mitochondrial clearance and elevated ROS levels in human iPSC-derived cardiomyocytes

    by Jianchao Zhang, Ying Peng, Wanrong Fu, Ruifei Wang, Jinhua Cao, Shuang Li, Xiaoxu Tian, Zhonggen Li, Chongpei Hua, Yafei Zhai, et al.

    Pleckstrin homology domain-containing family M member 2 (PLEKHM2) is an essential adaptor for lysosomal trafficking and its homozygous truncation have been reported to cause early onset dilated cardiomyopathy (DCM). However, the molecular mechanism of PLEKHM2 deficiency in DCM pathogenesis and progression is poorly understood. Here, we generated an in vitro model of PLEKHM2 knockout (KO) induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to elucidate the potential pathogenic mechanism of PLEKHM2-deficient cardiomyopathy. PLEKHM2-KO hiPSC-CMs developed disease phenotypes with reduced contractility and impaired calcium handling. Subsequent RNA sequencing (RNA-seq) analysis revealed altered expression of genes involved in mitochondrial function, autophagy and apoptosis in PLEKHM2-KO hiPSC-CMs. Further molecular experiments confirmed PLEKHM2 deficiency impaired autophagy and resulted in accumulation of damaged mitochondria, which triggered increased reactive oxygen species (ROS) levels and decreased mitochondrial membrane potential (Δψm). Importantly, the elevated ROS levels caused oxidative stress-induced damage to nearby healthy mitochondria, resulting in extensive Δψm destabilization, and ultimately leading to impaired mitochondrial function and myocardial contractility. Moreover, ROS inhibition attenuated oxidative stress-induced mitochondrial damage, thereby partially rescued PLEKHM2 deficiency-induced disease phenotypes. Remarkably, PLEKHM2-WT overexpression restored autophagic flux and rescued mitochondrial function and myocardial contractility in PLEKHM2-KO hiPSC-CMs. Taken together, these results suggested that impaired mitochondrial clearance and increased ROS levels play important roles in PLEKHM2-deficient cardiomyopathy, and PLEKHM2-WT overexpression can improve mitochondrial function and rescue PLEKHM2-deficient cardiomyopathy.